AURORA, ON, June 7 /CNW/ - Helix BioPharma Corp. (TSX, FSE: “HBP”) today announced financial results for the third quarter of fiscal 2006, ended April 30, 2006. The Company recorded a loss of $1,360,000 and $4,122,000 respectively for the three and nine month periods ended April 30, 2006 for a loss per common share of $0.04 and $0.13, respectively. In the comparative three and nine month periods ended April 30, 2005, the Company realized a loss $1,175,000 and $4,041,000 respectively for a loss per common share of $0.04 and $0.15, respectively.
